Evidence map›Paper›PMID 30687319›Full record

ArticleFrontiers in immunology2018

T Cell Response to Infliximab in Exposed Patients: A Longitudinal Analysis.

Sara Pratesi, Francesca Nencini, Francesca Grosso, Laura Dies, Susanna Bormioli, Daniele Cammelli, Enrico Maggi, Andrea Matucci, Alessandra Vultaggio, ABIRISK Consortium

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. CD4American journal of respiratory and critical care medicine · 2022
    Article
  4. Article
  5. Immunogenicity of TNF-Inhibitors.Frontiers in immunology · 2020
    Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Sara PratesiCentre of Research DENOTHE, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Francesca NenciniCentre of Research DENOTHE, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Francesca GrossoCentre of Research DENOTHE, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Laura DiesCentre of Research DENOTHE, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Susanna BormioliCentre of Research DENOTHE, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Daniele CammelliImmunoallergology Unit, Careggi University-Hospital, Florence, Italy.
Enrico MaggiCentre of Research DENOTHE, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Andrea MatucciImmunoallergology Unit, Careggi University-Hospital, Florence, Italy.
Alessandra VultaggioImmunoallergology Unit, Careggi University-Hospital, Florence, Italy.
ABIRISK Consortium
University of Florence · ITAzienda Ospedaliero-Universitaria Careggi · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to evaluate the proportion of infliximab (IFX)-exposed patients exhibiting cellular response to the drug in a longitudinal way and to establish whether it is predictive for anti-drug antibodies (ADA) development. Seventeen patients suffering from immuno-mediated disorders were enrolled. Blood was sampled at baseline and before each of the first eight infusions of IFX. The proliferation of PBMCs to 15-mer peptides covering VH/VL frames of IFX was assessed as well as transcription factors and cytokines mRNA expression of memory T cells in IFX-stimulated PBMCs. The number of peptides recognized by T cells after four infusions was higher than those recognized by the same patients before treatment. IFX-stimulated PBMCs from more than 90% of patients were able to express the main regulators and adaptive cytokines of memory T cells. While IFN-γ mRNAs increased after the first infusion and declined during the subsequent ones, IL-10 mRNA was upregulated throughout the treatment. IL-10 was functionally active because its neutralization improved IFN-γ and IL-13 mRNA expression

Indexed as

AdultAgedAntirheumatic AgentsArthritis, PsoriaticArthritis, RheumatoidDrug HypersensitivityFemaleHumansInflammatory Bowel DiseasesInfliximabInfusions, IntravenousInterferon-gammaInterleukin-10Longitudinal StudiesLymphocyte ActivationMaleAntirheumatic AgentsIFNG protein, humanIL10 protein, humanInfliximabInterferon-gammaInterleukin-10anti-drug antibodiesIFX-specific T cellsIL-10immunogenicityinfliximab

Identifiers

PMID30687319
PMCPMC6336713
OpenAlexW2905135203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.